Healthcare / BiotechnologyTaipei Exchange
$26.40
-0.60 (-2.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-285.8M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-52.3%
↓Gross Margin
63.7%
↑Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.1%
FCF CAGR
—
FCF margin
-484.7%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.4M · net income $-381.6M · FCF $-244.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.4M | $50.4M | $105.1M | $85.5M | $44.7M |
| Net Income | $-381.6M | $-381.6M | $-351.8M | $-217.5M | $-188.6M |
| EBITDA | $-249.2M | $-249.2M | $-247.4M | $-146.0M | $-129.5M |
| EPS | — | — | -4.81 | -3.80 | -3.78 |
| Gross Margin | 63.7% | 63.7% | 53.4% | 89.3% | 70.8% |
| Operating Margin | -762.0% | -762.0% | -334.4% | -251.1% | -417.1% |
| Net Margin | -756.8% | -756.8% | -334.7% | -254.5% | -421.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.44 | 0.44 | 0.29 | 0.44 | 0.54 |
| Cash Flow | |||||
| Free Cash Flow | $-244.4M | $-244.4M | $-363.3M | $-285.8M | $-223.2M |
| Returns | |||||
| ROE | -52.3% | -52.3% | -32.2% | -35.5% | -35.8% |
| Valuation | |||||
| P/B | 3.07 | 3.07 | 2.72 | 3.15 | 2.86 |
| Growth & Yield | |||||
| Revenue Growth | -52.0% | -52.0% | 23.0% | 91.0% | — |
| EPS Growth | — | — | -26.7% | -0.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.81 → n/d
Residual
-11.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.